Intensiva, Fundacion Jimenez Dfaz, 28040-Madrid, Spain, and tServicio de Endocrinolog(a, Hospital Ram6n y Cajal, 28034-Madrid, Spain Phospholipase A2 (PLA2) activity was purified 12 544-fold with a 13 % yield from the plasma of patients diagnosed of septic shock by the sequential use of heparin-agarose affinity chromatography, gel filtration, and reverse-phase f.p.l.c. Gel-filtration chromatography of plasma omitting high-ionic-strength buffer revealed a molecular mass different from that of purified PLA2 and co-elution with apolipoprotein A-I peaks, which suggests its association with high-density lipoproteins (HDL). N-terminal analysis of the enzyme activity protein band, electroblotted from a SDS-acrylamide gel and with an assessed molecular mass of 19 kDa, showed an identical sequence to that of a-chain of human C3 complement component, suggesting the presence in this band of a complex formed by a complement C3-derived anaphylatoxin (C3a)-related fragment and the PLA2 linked sideby-side. Because the preparation of plasma enzyme showed lower activity than the enzyme obtained from fibroblasts transfected with the coding sequence of human group-TI PLA2, and because the addition of C3-derived anaphylatoxins from human serum inhibited the activity of this recombinant PLA2, it was considered that C3a-related peptides behave as inhibitors of group-1I PLA2. The enzyme showed optimal activity on [14C]oleate-labelled autoclaved E. coli, on synthetic phosphatidylethanolamine, and on [3H]arachidonate-labelled membranes of the monoblast cell line U937, but it did not show any activity on the release of [3H]arachidonate from pre-labelled human polymorphonuclear leukocytes (PMNs). In short, PLA2 from plasma of sepsis patients shows unique associations with other plasma proteins which may influence its functional properties. The association with C3-related peptides shows an inhibitory effect on the enzyme activity, whereas the association with HDL might influence its environment and/or its interaction with cells. The study of the catalytic properties shows a prominent effect on bacterial phospholipids, synthetic phosphatidylethanolamine, and membranes from U937 monoblasts, but not on synthetic phosphatidylcholine or on PMNs, even when these cells were maintained in culture to allow spontaneous apoptosis and became a good substrate for pancreatic type PLA2.
INTRODUCTION
Phospholipases A2 (phosphatide sn-2-acylhydrolases, PLA, EC 3.1.1.4) from mammalian tissues play a role in physiological functions such as defence mechanisms and the production of bioactive lipids [1, 2] . Although these functions of PLA2 seem relevant to the pathogenesis of various clinical conditions including rheumatoid arthritis and septicaemia [3] [4] [5] [6] , the pathobiology related to abnormal production of extracellular PLA2 is not clearly defined. Within the past two years recombinant human group-II PLA2 of 14 kDa molecular mass, identical to that found in platelets [7, 8] , placenta [9] , synovial fluid [8] , spleen [10] and plasma [11] , has become available and has been employed to evaluate its extracellular function in different in vitro models. Unlike snake venom PLA2, pure recombinant human group-II PLA2 does not express inflammatory activity in normal rat tissues [12, 13] , although a role for this enzyme in the propagation of cell-mediated inflammatory processes has been proposed because of its ability to produce activation of Tlymphocytes [14] and degranulation of mast cells [15] . Current views stress the role of the 14 kDa group-II PLA2 as an acutephase protein secreted from liver cells in response to inflammatory stimuli [16] , and the recent cloning of a 1 kbp cDNA encoding a novel human low-molecular-mass PLA2 [17] lends support to previous biochemical studies pointing to the existence of distinct PLA2 genes in humans. On the other hand, the characterization of phospholipases from mononuclear phagocytes [18] [19] [20] [21] , kidney tissues [22] , guinea-pig intestinal brush-border membranes [23] and, most recently, rabbit [24] and human [25] platelet cytosol has disclosed both functional and structural properties different from those of the above reported enzymes, being of remarkable importance higher molecular sizes and coupling to the release of arachidonic acid induced by hormones and growth factors.
The data presented in this paper indicate that the group-II PLA2 from septic patients' plasma shows a unique pattern of interaction with plasma proteins: an association with highdensity lipoproteins (HDL) that can be reversed by high concentrations of salt, and a more stable interaction with peptide chains with complete identity to the N-terminal portion of the axchain of human C3. The association of PLA2 with complement component C3-derived anaphylatoxin (C3a) seems to explain the inhibition of activity observed in the samples of enzyme purified from plasma compared with that purified from the culture media of fibroblasts stably transfected with the coding sequence of group-II PLA2. Plasma PLA2 shows activity on bacteria, synthetic phosphatidylethanolamine, and isolated plasma membrane fraction from [3H]arachidonate-labelled U937 monoblasts, but not on synthetic phosphatidylcholine or the phospholipids of [3H] arachidonate-labelled human polymorphonuclear leukocytes (PMNs). The different effects of PLA2 on membranes from U937 monoblasts and PMNs points to cell-specific mechanism(s) for the interaction of the enzyme and its substrate in cell membranes.
EXPERIMENTAL Patients and materials
Plasma from patients with sepsis was obtained from venous blood anticoagulated with heparin. Sepsis syndrome was defined according to the criteria of Bone et al. [26] , and APACHE II score was used for disease severity classification [27] . [1-_4C] Oleate (53.9 mCi/mmol), [9,10(n) -3H]palmitate (53.4 Ci/mmol), 1- stearoyl-2 [5,6,8,9,11,12,14, Assays of PLA2 activity The assay was routinely carried out with either 0.5 ,ul of patients' plasma, 20 ,ul ofthe chromatography fractions, or the appropriate volume of concentrated pooled fractions in a total volume of 0.1 ml, according to the procedure of Elsbach et al. [31] . A batch of plasma was exposed to sulphuric acid extraction [7, 8] before the aforementioned purification procedure to assess the effect of this treatment on the removal of possible inhibitors of PLA2.
Purification of human recombinant group-il PLA2 and preparation of a rabbit polyclonal antibody Supernatants from cultures at superconfluence of line C127 mouse fibroblasts stably transfected with the coding sequence of group-lI PLA2 from human placenta [29] were used as a source of human recombinant group-II PLA2. To facilitate the purification of the secreted enzyme, the concentration of heatinactivated fetal calf serum was reduced to 5 % and supernatants were collected every 48 h. The purification protocol used to obtain a preparation suitable for the assay of enzyme activity was similar to that applied for the plasma PLA2.
When the purpose of the experiment was to obtain a homogeneous preparation that could serve for both unambiguous characterization of its molecular mass and to produce a rabbit polyclonal antibody, an additional chromatography was performed using a C18 reverse-phase h.p.l.c. column (Nova-Pak 15 cm x 3.9 mm, Waters), which was operated at room temperature at a flow rate of 0.5 ml/min with an 80 min gradient counting. Studies directed to assess positional specificity of the using the acetonitrile-based mobile phase described above. This Hepes-buffered medium, pH 7.4, containing 0.25 % essentially fatty-acid-free BSA, in the absence of Ca2+ ions, according to the procedure described in [36] . At [30] . RESULTS PLA2 from patients' plasma is associated with HDL and fragments from complement C3 component Initial strategies of purification were based on the utilization of gel-filtration chromatography in view of the low molecular mass of most PLA2s, which allows a good separation of these polypeptides from plasma proteins [37] . Other criteria were the use of samples from the same patient until the purification procedure was found to give reliable results, and omission of drastic treatments such as sulphuric-acid extraction which might influence the environment of the enzyme, and has been shown to inactivate high-molecular-mass PLA2 [38] . Table 1 summarizes clinical data of the group of patients used to carry out the study. Initial attempts to use gel-permeation chromatography techniques were carried out with an analytical Superose 12 HR 10/30 column. We found a changing pattern of elution of the enzyme activity depending on the molarity of the buffer. In fact, when the column was eluted with buffer containing 0.4 M NaCl, PLA2 eluted as a single peak, with a molecular mass smaller than that of serum albumin (Fig. la) . In contrast, when the chromatography was carried out in a medium containing 0.10-0.25 M NaCl, enzyme activity eluted with the peak of protein being excluded. This finding prompted us to use supplementary gelpermeation chromatographic conditions before drawing conclusions on the apparent molecular mass of PLA2. As shown in Fig. 1(b) , PLA2 from patients' plasma eluted with a molecular mass > 160 kDa when chromatographed in a Superose 6 HR 10/30 column in a medium containing 0.1 M NaCl. PLA2 coeluted with two apo A-I peaks, but no activity was found associated with either of the apo B peaks. This suggests an association with some particles of HDL of plasma PLA2 [39] but not with very-low-density lipoprotein or low-density lipoprotein.
The final schedule of purification ( NaCl. The Figure  3 ). The N-terminal amino acid sequence of the active protein band was SVQLTEKRMD, which is identical to the reported achain of human C3 complement component and also to the other 12 kDa protein band. The relative yields in each degradation cycle of both protein bands were nearly the same. These findings could be consistent with several hypotheses, but taking into account the sequence of the PLA2 from septic shock patients [11] and its molecular mass, the most likely interpretations suggest either N-terminal blockade of the plasma PLA2 or small amounts of protein strongly associated with C3a-related peptides. Because attempts to further separate PLA2 activity from an associated C3a-related contamination using ionexchange, hydroxylapatite-based chromatography and analytical gel filtration were unsuccessful, the existence in the 19 kDa activity band of a complex formed by a C3a-related fragment and the PLA2 linked side-by-side, which could explain the unique N-terminal sequence obtained in such a protein gel band, can not be discarded (see below). Figure 4 ). Recombinant purified PLA2 and pancreatic PLA2 showed higher activities under these conditions. Unlike plasma PLA2, they hydrolysed up to 90 % of total phospholipid ( Figure 4 ). As this finding suggested the presence of an inhibitor in the samples of plasma PLA2, and this preparation contained fragments of C3 achain, the inhibitory effect was attributed to this peptide(s). This possibility was tested by looking for PLA2 inhibitory activity in serum activated by zymosan. The fraction corresponding to -9 kDa obtained by gel-filtration chromatography of zymosanactivated human serum induced a dose-dependent inhibition of the recombinant enzyme ( Figure 5 ), whereas no inhibitory effect could be detected in any other fraction. As the size of this fraction corresponds with that of C3a des Arg, this result is in keeping with the inhibitory effect of C3 a-chain related products on group-II PLA2. The possibility that sulphuric-acid extraction could produce the removal of inhibitory peptides for PLA2 activity in plasma was tested in a sample exposed to this treatment before the standard purification protocol. As shown in Figure 4 , The experimental conditions were analogous to those used in Figure 4 , except that t.l.c. was carried out at the end of the incubation period to separate free fatty acid from phospholipids. The samples used were: patients' plasma PLA2 (0). recombinant human PLA2 (O), and porcine pancreatic PLA2 (h). remaining PLA2 activity. As shown in Table 4 , PLA2 activity was significantly removed by the polyclonal rabbit antibody.
Effect of purffled PLA2 on [3H]arachidonate-labelled membranes from U937 cells component of bacterial membranes. Additional experiments directed to assess PLA2 selectivity towards the fatty acid at the sn-2 position were carried out on mixed substrate at a PC/PE ratio of 1.0, which is consistent with lamellar structure [41] , to avoid a possible bias on the appraisal of specificity caused by the effect of the polar head on the physical conformation of vesicles [42, 43] . As shown in Table 3 , a preference for arachidonoylcontaining molecular species or for alkyl-ether-linked GPC was not observed. Plasma PLA2 showed optimal activity at micromolar Ca2+ concentration as well as at physiological pH (results not shown).
Effect of anti-(group 11 PLA2) antibody on PLA2 activity from patients' plasma Both patients' plasma PLA2 and recombinant PLA2 were incubated for 1 h at 37°C with different amounts of the antiserum raised against recombinant PLA2. At the end of this period, protein A insolubilized on Sepharose CL-4B was added to the medium. The mixture was centrifuged at 10000 g in an Eppendorf microcentrifuge and the supernatants used for the assay of the In keeping with the results obtained in the E. coli assay, saturation occurred at different extents of hydrolysis for each enzyme (Figure 6a) . It was considered again that the association of C3 achain fragments with the plasma enzyme could account for the differences in activity. Figure 6(b) shows the time course of hydrolysis of [3H]arachidonate from membranes of U937 cells. Analysis of the extent of hydrolysis of the different phospholipid classes showed hydrolysis of 19 +4% (mean+S.E.M., n = 3) of the [3H]arachidonate associated with PE by the plasma enzyme, and a slightly smaller activity on PC (12 + 2 %), whereas the rate of hydrolysis of either phospholipid class with the recombinant enzyme was 45 + 7 % on PC and 37 + 6 % on PE (n = 3). This result in combination with the aforementioned data on synthetic substrates indicates that the preferential action of group-II PLA2 on different phospholipid classes could be explained by structural features influencing enzyme-substrate interaction, rather than by selectivity of the enzyme for either the polar head or the fatty acid substituting at the sn-2 position. under conditions where both ionophore A23187 and N-formylmethionyl-leucyl-phenylalanine (fMLP) did so (Table 5) . Similar experiments performed on [14C]oleate-labelled PMNs also showed the lack of fatty acid release. Because it has been reported that the normal location of phosphatidylserine on the inner leaflet of the plasma membrane is lost during apoptotic death of PMNs [44] [45] [46] , and because this may lead to an enhanced expression of anionic phospholipid to the outer leaflet, with possible consequences for the interaction of the enzyme with the lipid membranes, PMNs were maintained at 37°C for different periods of time, in order to allow for the appearance of spontaneous apoptosis and expression of phosphatidylserine on the outer layer. Under these conditions only group-I PLA2 provoked release of free fatty acid above the control level ( Figure  7 ). When the experiment was carried out using isolated plasma membranes from PMNs, again only the pancreatic PLA2 displayed hydrolysis of the phospholipid (44 ± 4% on PC and 40 + 3 % on PE, n = 3). Taken together, these data indicate a poor capacity for group II PLA2 to hydrolyse phospholipids on PMN membranes, whereas group-I PLA2 showed this ability both in populations of PMNs which contained a high number of apoptotic PMNs and on PMN isolated membranes.
DISCUSSION
This paper provides new results on PLA2 activity in plasma of patients with sepsis syndrome regarding association with proteins which could influence its catalytic properties and its functional role. Our data indicate that the plasma enzyme exists in a highmolecular-mass complex which elutes under gel-permeation chromatography within a volume that is characteristic of the molecular mass of some particles of HDL [39] . This association with HDL particles is also suggested by the co-elution with both apo A-I apolipoprotein peaks, although preferentially with that showing a higher molecular mass. The chance of a reversible association with PLA2 of some HDL particles is supported by the effect of high-ionic-strength treatment, which yields a PLA2 showing a lower molecular mass.
The retarded elution of PLA2 compared with apo B strongly suggests that this enzyme is not the form of PLA2 associated with apo B, which acts on oxidized phospholipids, associates with low-density lipoprotein and shows a molecular mass > 66 kDa [47] . This finding is reminiscent of reports on some enzyme activities secreted by liver cells and mononuclear phagocytes that are incoporated into a lipoprotein particle, e.g. lecithin-cholesterol acyltransferase [48] and PAF-acetylhydrolase [49, 50] . This is also consistent with the report of the induction of group-II PLA2 gene expression in human hepatoma cells by mediators of the acute-phase response [16] , and with the stimulation of PLA2 synthesis and secretion by rat liver after injection of bacterial endotoxin [51] .
Another association with PLA2 herein disclosed is that of a polypeptide from the complement system. This is sustained on our inability to isolate the plasma enzyme from peptides showing the N-terminal sequence of the C3 a-chain [38] after a number of treatments. The formation of cross-linking between C3a and PLA2 via intermolecular disulphide bridges seems a likely mechanism that could explain a side-by-side interaction of PLA2 with a fragment of C3a. The reported ability of group-II PLA2 to produce multimeric forms even in the presence of SDS and dithiothreitol [52] , and the existence of six cysteine residues in C3a support this interpretation, but further analysis of this possibility was thwarted by the sensitivity of PLA2 activity to sulphydryl reducing agents [53] . This association seems of functional significance, as the production of group-IT PLA2 and C3 appears to take place simultaneously. Thus, expression of the human C3 gene is tissue-specific, with hepatocytes being the main site of synthesis [54] .
Production of C3 has also been found in the human hepatomaderived cell line HepG2 [55] , and C3 is an acute-phase reactant whose production is increased during acute inflammation in response to interleukin-1 [56] and tumour necrosis factor-a [57] in a similar manner to the cytokine-mediated induction of the PLA2 gene in HepG2 cells [15] . In addition, bacterial endotoxin is a strong initiator of complement activation that produces the generation of C3as. Because We have not addressed as yet an analysis of the mechanism of inhibition of PLA2 activity by the C3a-related moiety, but the close association with the enzyme, and the finding in preliminary experiments that optimal effect is obtained when the inhibitor is incubated with recombinant PLA2 before the addition of substrate, would suggest the need for interaction of both peptides in the aqueous phase, rather than association at the interface or depletion of substrate [58] . As far as we know, there is only one report indicating that degraded products of C3 show inhibitory effects on rat peritoneal group-I1 PLA2, but not on phospholipases from bee venom, Naja naja venom, and porcine pancreas [59] . However, that study was directed to investigate inhibitory proteins on the PLA2 assay, rather than to search for inhibitory proteins associated with the enzyme. In addition, the portions of the C3 molecule isolated start from either residue 289 or 326 of the a-chain of human C3, and belong to a region of C3 complement component with a functional role different from that of the C3a fragment.
Another association of complement and PLA2 has emerged from the recent description of the requirement for membraneassociated PLA2 in platelet cytotoxicity induced by receptors for IgG and complement [60] ; however, neither the type of PLA2 involved in this reaction nor the precise nature of the bound C3 fragment has been characterized, although it has been shown that the complete cytotoxic system may exist as a preformed complex in platelet membranes.
As regards functional properties, the group-IL PLA2 used in this study showed a preferential activity on the E. coli assay, on synthetic PE and on U937 monoblast cell membrane fractions. Because U937 cell-line membranes should resemble the structure found in host cells, this prompts a search for an explanation for the lack of effect of group-LI PLA2 on PMNs maintained in culture to undergo spontaneous apoptosis and expression of phosphatidylserine on the outer leaflet of the plasma membrane [44] [45] [46] , and even on isolated membranes from [3H]arachidonatelabelled PMNs. This puzzling finding contrasts with the concomitant evidence of hydrolysis of phospholipids from both ageing PMNs and PMN isolated membranes by group-I PLA2.
Two conclusions can be drawn from these findings: (a) ageing of PMNs is sufficient to convert these cells into a good substrate for group-I PLA2, but not for group-II PLA2; and (b) some structural features in U937 monoblast cell membrane allow its recognition by group-II PLA2. This observation could be related to recent reports on macrophage-like P388D1 cells [61] , rat connective tissue mast cells [14] , and endothelial cells [62] , that indicate regulation of group-LI PLA2 by interaction between cell-surface heparan sulphate and the heparin-binding domain of the enzyme. Alternatively, we can not rule out the existence of cell-surface binding sites similar to that demonstrated for group-I PLA2 in several cell types [63] . Although our data do not show a role for group-II PLA2 in the initiation of the lipid mediator cascade in PMN, or in the generation of prostaglandin D2 from rat mast cells [141, our results would agree with the possible involvement of group-IL PLA2 in the production of eicosanoids from macrophage-type cells [61, 64] , and with a role for this enzyme in the modulation of arachidonate metabolism in chronic inflammation rather than in the acute setting of bacterial invasion where PMNs operate. Moreover, from studies in animal species other than human, it is now apparent that both normal rabbits [5] and rats [65] have plasma concentrations of PLA2 similar to those detected in humans with sepsis, whereas they do not show the pathophysiological consequences of an enhanced production of lipid autacoids. Finally, taking into account the association with lipoproteins of PLA2, and the newly described pathway selectively related to the low-density lipoprotein receptor [66] that allows the delivery of arachidonate for eicosanoid production, we can not rule out a similar mechanism linked to HDL.
